We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Xenetic Bio | LSE:XEN | London | Ordinary Share | GB00B08NWV55 | ORD 0.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | GBX |
Xenetic Bio (XEN) Share Charts1 Year Xenetic Bio Chart |
|
1 Month Xenetic Bio Chart |
Intraday Xenetic Bio Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 05/7/2018 | 17:42 | Xenetic Biosciences - A pipeline with a multi-billion dollar market potential | 1,369 |
| 13/11/2013 | 08:23 | XENOVA- take over target or biotech success? | 2,145 |
| 22/6/2013 | 22:13 | XEN - new name for Lipoxen - still crap | 6 |
| 05/5/2009 | 21:29 | Xenova: Chance to make a shilling pt 2 | 651 |
| 16/5/2005 | 21:31 | Xenova group - your warrant to big profits | 71 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 05/10/2017 18:03 by corrientes Broker saying 'XEN' could reach $10,but any research not in public domain yet. |
Posted at 22/8/2016 02:43 by buywell3 Re post 1341 and 1342Note the references to Peter Laing of excivion ltd Regards what he has previously achieved at Lipoxen ( which was the old name for Xenetic Biosciences when it was based in the UK ) Check out his achievements were and are now. They are set to earn $'s for XEN and this new deal re Zika could now add to that see So it looks a good tie up/deal pre floatation to me Track Record of Invention Peter Laing, CEO, has a strong track record of invention that has given rise to notable licensing deals with major pharma and biotech companies. As a Lecturer in Immunology at the Univesity of Nottingham he filed one of the first patents on luminescent DNA sequencing; at Peptide Therapeutics plc (later Acambis) as Director of Research he pioneered 'Molecular Vaccine Design' patenting peptide mimics of the capsular polysaccharide of the group-B meningococcus as vaccine immunogens; at Lipoxen plc he was responsible for development of the 'Virtual Conjugate Vaccine' that was licensed to Serum Institute of India Ltd for a 14-component pneumococcal vaccine (wherein liposomal formulation takes the place of chemical conjugation); at Lipoxen (now Xenetic) as Chief Operating Officer he was also responsible for their 'Co-Delivery' technology which exploits DNA and protein representations of an antigen in the selfsame particle effecting dramatic improvements in vaccine potency (allowing single-dose), exemplified with influenza and hepatitis-B vaccines. At Lipoxen he also developed long-acting versions of factor-VIII in collaboration with Baxter, and a next-generation EPO (ErepoXen) for anaemia, now in phase-III. At United Therapeutics Corp/Europe Ltd he was in charge of their hepatitis-C programme and an inventor of diagnostic and therapeutic patents in the field of flaviviruses, notably UV4B - an oral broad-spectrum antiviral agent now licensed to Emergent for dengue. These finely tuned inventive skills are now dedicated to Excivion in pursuit of its New Pharmaceutical Model. |
Posted at 11/8/2015 16:21 by buywell3 Why Global Healthcare Companies Have Invested in Xenetic BiosciencesPosted on August 6th, 2015 My name is Scott Maguire, CEO of Xenetic Biosciences, Inc. (OTCQB: XBIO), and I am pleased to welcome you to my inaugural blog. As we are fairly new to the US, I would like to use this opportunity to introduce you to Xenetic and our promising novel drug developments that we are driving through clinical trials with some of the world’s leading players in healthcare. Xenetic was founded in 1997 as a spin off from University College London School of Pharmacy by Professor Gregory Gregoriadis, one of the leading researchers in drug delivery. As a result of his and our research and development team, the Company holds over 147 US and international patents issued and more than 90 patents pending. This is by any measure a vast patent estate, especially for a small cap biotech company. It is our expectation that, as Xenetic grows its capital base, we will be able to use these patents to create more novel therapies and ultimately contribute to improving global health. In January of 2014, Xenetic relocated its research base from London to Lexington, Massachusetts, just north of Boston, tapping into the wealth of talent in orphan drug development and market launch expertise in the greater Boston area. At the same time, the Company completed a public listing in the US on the OTCQB with the hope of raising the magnitude of capital required to drive our drug candidates through clinical development providing the potential for an eventual market launch. Although Xenetic Biosciences is only a small company at present, I believe that the future and outlook is bright given the scale and importance of our current license deals as well as our strategic shareholders and proprietary drug candidates. We are fortunate to have several cornerstone and deep-pocketed investors who have invested the majority of the invested capital to date. These cornerstone shareholders include Rusnano via SynBio (XBIO was one of their first biotech investments), the Serum Institute of India, India’s largest biotech company and one of the world’s largest vaccine manufacturers, and Baxter International (NYSE:BAX), one of the world’s largest biopharma companies. This stable shareholder base is fully supportive of the Company’s stated ambition to up-list its shares onto a globally recognized, more liquid securities exchange such as NASDAQ, which better represents the Company’s potential and value. Baxter is the most recognized name associated with Xenetic. Our license deal with Baxter involves developing drug candidates with an extended half-life of certain proteins and molecules using the Company’s patent-protected PolyXen® technology(utilizing chains of polysialic acid “PSA”), designed to create a longer-acting hemophilia drug than what is currently on the market. PolyXen® works by attaching a PSA chain to the drug with the objective of making the drug stay in blood circulation much longer and protecting the drug from the body’s immune system. The design of the PolyXen® technology is intended to make the drug more effective, last longer and decrease the frequency and amount of the drug. Baxter expects to commence human clinical trials on this novel hemophilia drug candidate during the first half of 2016. Baxter is a major license partner of Xenetic, having expanded an existing license agreement with us last year. The agreement now equals $100M in potential cash payments to Xenetic in addition to royalty payments. Baxter is also a significant shareholder in Xenetic, most recently investing $10M at a price of approximately $0.94 per share, which represented a market cap of $140M at that time. A second important initiative for Xenetic is our early stage, yet very promising drug candidate, OncoHist™, which has the potential to be a game-changer in cancer therapy. This is a drug candidate based on histone proteins that are known to naturally act against cancer cells. The base material is harvested from human cells, and when developed into OncoHist™ has shown initial promise in small clinical trials (40 subjects) in both Germany and Russia for the treatment of Acute Myeloid Leukemia (AML) and Non-Hodgkin’s Lymphoma (NHL). Our hope is that further clinical study will demonstrate that OncoHist™ provides benefit without the toxic effects of the current standards of care which destroy healthy cells as well as cancer cells. Based on the initial European clinical data, the Dana Farber Cancer Institute, one of the world’s leading cancer medical centers, signed on as an active partner in our US clinical pursuits and is currently conducting preclinical research in the US on OncoHist™ for other indications beyond AML. It remains our priority to commence US clinical trials with OncoHist™ under an orphan drug designation for AML, followed by clinical trials for other rare cancer indications, dependent upon Xenetic’s available capital resources. Yet another important initiative, and our most advanced clinical candidate, is ErepoXen® (polysialylated erythropoietin (“PSA-EPO̶ The Company’s commercialization strategy for ErepoXen®, which we believe could be a mainstream drug addressing a substantial global market, includes seeking an out-license arrangement for the continuing development of ErepoXen® as a potential Phase II(b) candidate. Xenetic is looking for a well-capitalized license partner who is more experienced at taking large market drug candidates through the latter stages of human clinical trials and who would be better placed to execute a global market launch. I want to thank you all for taking the time to read Xenetic’s first CEO blog. The Xenetic team and I look forward to updating you on the Company and providing insights on the therapeutic areas where we hope to make a difference. Sincerely, Scott Maguire |
Posted at 11/8/2015 16:18 by buywell3 Xenetic Biosciences, Inc. – "Why Global Healthcare Companies Have Invested in Xenetic Biosciences"08/06/15 NEW YORK, NY / ACCESSWIRE Xenetic Biosciences, Inc. (OTCQB: XBIO) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Scott Maguire, MBA. TheChairmansBlog.com is an exclusive on-line media publication that enables key executive officers a unique platform to share insights about their company and industry trends. In his inaugural blog, Scott Maguire discusses Xenetic's promising novel drug developments and partnerships with leading world healthcare companies such as Baxter International (NYSE: BAX). He expands on the progress of the Company's main initiatives PolyXen(R), OncoHist(TM), and ErepoXen(R) and shares Company goals moving forward. Read the full blog post from Mr. Maguire on TheChairmansBlog.com ( About Xenetic Biosciences Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen(R), designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs, and OncoHist(R) for the development of novel oncology drugs focused on orphan indications. Xenetic's lead product candidates include ErepoXen(R), a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and OncoHist(R), a novel recombinant human histone H1.3 molecule for the treatment of refractory Acute Myeloid Leukemia (AML) with potential to treat numerous other cancer indications. Xenetic is collaborating with Russian-based OJSC Pharmsynthez (who is an affiliate of a significant shareholder in Xenetic) and the Serum Institute of India to test additional drug and vaccine candidates and to de-risk the development process with clinical data generated in Russia and India before Xenetic takes these candidates into the clinic in the Western markets. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company's website at www.xeneticbio.com. Baxter Healthcare: Xenetic is working together with Baxter International Inc. to develop a novel series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on the PolyXen technology to conjugate PSA to therapeutic blood-clotting factors, with the goal of improving the pharmacokinetic profile and extending the active life of these biologic molecules. Baxter is one of the Company's largest shareholders having invested in a number of rounds with the most recent investment of $10M last year. The agreement is exclusive research, development and license agreement grants Baxter a worldwide, exclusive, royalty-bearing license to Xenetic's PSA patented and proprietary technology in combination with Baxter's proprietary molecules designed for the treatment of blood and bleeding disorders. Under the agreement, Xenetic may receive regulatory and sales target receipts for total potential milestones of up to $100 million plus royalties on sales. About TheChairmansBlog.com TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog SOURCE: TheChairmansBlog.com |
Posted at 04/6/2014 07:26 by buywell2 worth another readRAY DIRKS RESEARCH: Xenetic Biosciences (XBIO) Feb 27, 2014 by Ray Dirks February 27, 2014 Xenetic Biosciences Inc is an under-followed clinical-stage bio-pharmaceutical company. Xenetic was previously based in the United Kingdom and has relocated its labs and headquarters to Lexington, Massachusetts in the United States. The company has delisted itself from the AIM exchange and is currently listed on the OTCBB (XBIO). Xenetic will seek a NASDAQ listing by year end 2014. The company is very unique in that the largest shareholders are some of the leading commercial biotech companies on the planet. SynBio, the largest shareholder, is controlled by RUSNANO the Russian government controlled fund responsible for building the biotech industry in Russia. Baxter, the second largest shareholder, is one of the worlds largest biotech companies. Baxter has become the second largest shareholder as a result of the investment recently announced . Serum Institute of India, the third largest shareholder, is the world's largest vaccine manufacturer and India's largest biotech company. So the shareholder list is one of the most impressive of all the biotech companies I have seen. Xenetic has approximately 15 products under license or in development under a management that has a wealth of experience in the healthcare field in terms of creating, developing, and bringing to the marketplace a variety of drug and drug-delivery products. So the company has MANY shots on goal and is atypical of biotech companies which rely on one or two drugs. The novelty of the company lies in its approach to de-risking biotech by licensing out Russia and India to its shareholders and license partners who then provide human proof of concept data. This data determines with a high degree of confidence whether the drug will be successful in Western trials. The company then pursues US and European clinical trials under a derisked program. So the combination of many shots on goal with a number of different technologies with clinical data funded by large shareholders makes this company very unique and with a model that should be the looked at by all other US biotechs as a means to derisk biotech. It was recently announced that Baxter invested $10M into the company at a valuation of $140M post money. Baxter sees this as such an important license deal for the core of their franchise, hemophilia, that Baxter has substantially increased the cash milestones payable to $100M as well as substantial royalties payable on sales. The Company also recently announced the appointment of a director. Dr Tim Cote, who was former head of the Orphan Drug division at the FDA. Dr Cote brings significant US FDA regulatory expertise that will be invaluable in the company's pursuit to develop and launch the many novel and next generation orphan drugs in its pipeline, including acute myeloid leukemia, cystic fibrosis, and hemophilia. RAYDIRKS Research suggests that Readers of this article do their due diligence and then consider taking positions in the common stock of Xenetic Biosciences for the possibility of substantial capital appreciation over the long term. Specifically, we think that those who take positions in Xenetic in the the 200 to 250 million dollar market capitalization area, have a good chance of seeing their investment advance in price by 5 to 7 times over the next 3 to 5 years. Let's start with a description of the Xenetic Biosciences management team: Mr. M. Scott Maguire Chief Executive Officer. Mr. Maguire joined Xenetic Biosciences in April, 2004 as CEO. Scott's investment background is in life sciences and healthcare investment banking. He led the companies listing in London and the many license deals and capital raises that have been completed by the Company over the last 10 years. He has advised many U.S. and European company's capital raises, and also its commercial development over the past 22 years. In 1996 he co-founded the Arthur Andersen global healthcare corporate finance practice based in London. Scott is now director of Healthcare Capital Partners Limited, a healthcare corporate finance and proprietary investment boutique that he co-founded in 2002. He is also a co-founder and director of Renal Services Ltd, a privately held dialysis services business with clinics across the UK. Dr. Henry Hoppe IV, PhD, Director of Drug Development. Dr. Hoppe is a biotechnology process development executive with over 20 years experience in recombinant protein, monoclonal antibody, and stem cell expression for clinical therapies. Henry graduated with a PhD in genetic technology from MIT in 1980. Between 1980 and 1984, Henry held positions at the Harvard Medical School and the University Hospital of Boston. From 1984 to 2001, Henry worked for Genzyme Corporation, focusing on therapies for rare genetic diseases. In 2004 Henry founded his own consultancy business to provide expertise on advancing therapies from research into Phase I and Phase II clinical trials. Sir Brian Richards, , CBE, B.Sc., Ph.D., D.Sc. Sir Brian Richards was appointed non- executive Chairman of Xenetic in June 2005. During the 90s he was regarded as one of the leading figures in UK biotech. He was knighted by the Queen for his extensive work in the biotech sector, dating back to his early days working with Watson and Krick on DNA structure. He has extensive experience of chairing boards of UK public companies having been chairman of Alizyme plc, Cozart plc, VASTox plc and MAN Mali (Guernsey) Limited. Sir Brian previously served as executive Chairman of British Biotechnology Plc, a company he co-founded, which reached FSTE 100 status and has had non-executive chairmanships or directorships of several biopharmaceutical companies including Peptide Therapeutics (later Acambis plc), Oxford Biomedica plc and CeNeS Pharmaceuticals plc. Mr. Colin William Hill, ACMA, Chief Financial Officer. Mr. Hill was appointed Chief Financial Officer at Xenetic Biosciences in June, 2007. Before joining Xenetic, he was finance Director (2001-2003) and non-executive Chairman (2002) at Greenchip Investments plc. Colin has been a member of the Chartered Institute of Management Accountants since 1968 and spent 15 years in industry specializing in corporate turnaround and development work before becoming a freelance consultant in 1981. The accomplishments of this talented and experienced management team while they've been running Xenetic Biosciences are impressive to those observers of the enormous healthcare and medical biotechnology area who have come across Xenetic, but so far there has been very little promotion of the company in terms of publicity or public relations, either within the industry or the in the financial world. Consequently, the stock of Xenetic Biosciences remains under-valued. RAYDIRKS Research is writing this initial article on Xenetic Biosciences and will issue regular, and timely, follow-up reports directed to the financial community, particularly to those who have demonstrated an interest in early-stage medical biotechnology companies that have started clinical trials in the United States and/or in other countries. Xenetic Biosciences is a clinical stage bio-pharmaceutical company based Lexington, MA. Xenetic provides expertise in the development of next generation drugs, new cancer drugs and vaccines. Xenetic Biosciences partners with some of the largest pharmaceutical companies in the world who also happen to be the largest shareholders providing specialist delivery solutions to improve the efficacy, reducing the dosing and performance of drugs and vaccines in several key medical areas. Xenetic Biosciences is also actively developing its own pipeline of next-generation orphan bio-therapeutics based on its proprietary platform technologies as well as novel treatments for rare leukemias. Xenetic Biosciences has a $100M license agreement (cash payments linked to milestone achievements) with Baxter International to develop a series of blood coagulation factors, including Factor VIII for hemophilia, an orphan indication. {Eight companies, whose factor products are registered in the United States, currently split the $3 billion United States marketplace: Baxter Healthcare, Bayer HealthCare, CSL Bering, Grifols, Novo Nordisk, Talecris (formerly Bayer Plasma Division), Pfizer (formerly Wyeth), and Octapharma.) Xenetic Biosciences has collaboration agreements with several companies, including SynBio, The Serum Institute of India, and Pharmasynthez. Xenetic Biosciences has approximately 15 products under license or under development currently, including next generation biologics, vaccine, and novel oncology drug candidates. At the center of Xenetic Biosciences' strategy are 3 proprietary drug and delivery platforms which enable the creation of novel and next generation drug and vaccine candidates with improved performance and with applications over a broad range of therapeutic areas. The platform technologies of Xenetic Biosciences are: PolyXen - a known natural bio-polymer that is designed to extend the length of action of drugs in the body. PolyXen is an enabling technology for protein drug delivery that uses the bio-polymer polysialic acid to prolong the active life and to improve the pharmokinetics and pharmocodynamics of therapeutic peptides and proteins. PolyXen is a designed to be next-generation method to the highly successful PEGylation (PEG) for the delivery of protein drugs. PEG is currently a multi-billion dollar delivery agent used on blockbusters like Neulasta from Amgen and Pegasys from Roche. Of great importance, Xenetic Bioscience's lead drug candidate is based on existing marketed bio-similar drugs and a known method of polymer attachment. OncoHist - a novel therapeutic platform for various cancer indications, OncoHist is a technology that uses the properties of human histone, H1.3, a critical component of the innate defense system for the treatment of cancer. This technology was obtained by means of Xenetic Biosciences' acquisition in 2011 of SymbioTec, a German company. (SymbioTec was a developer of the technology that uses highly-alkaline proteins to treat a broad spectrum of cancers). OncoHist has strong anti-proliferative properties in cancer cells of different histological origins. This has been demonstrated extensively for hematologic malignancies (e.g., leukemias, lymphomas, and myelomas) and has the potential application across a broad spectrum of other cancers, 60 identified to date in many studies.. Lastly ImuXen - a novel liposome encapsulation to create new vaccines and to improve existing vaccines, ImuXen is an enabling technology that utilizes liposome-based constructs to boost the effectiveness of DNA, protein, and polysaccharide vaccines. ImuXen can achieve protective immunity in a single dose. Currently Xenetic has a Multiple Sclerosis program licensed to Pharmsynthez, which has started PH II trials in Russia. This is a very novel drug candidate so the Company will await patient data out of Russia before deciding if and how to proceed with this vaccine. In summary, all technologies are in Phase II or beyond. Xenetic Biosciences' pipeline of about 15 products contains several drug candidates that are currently in clinical trials which offer improved performance, reduced dosing and delivery characteristics. The delivery technologies of Xenetic Biosciences also have the potential to create new, high-value, differentiated proprietary products from off-patent drugs. Xenetic Biosciences hopes to make a number of Investigational New Drug Applications ("IND") filings in the U.S. at the end of this year and into next year. based on and assuming continued successful clinical outcomes. These filings are as follows: PolyXen a Phase II clinical trial in Australia and New Zealand. ErepoXen, (the lead drug candidate within the PolyXen platform) for the treatment of anemia, is scheduled to report in May. Phase II clinical trials are pilot clinical trials to evaluate efficacy and safety in selected populations of patients with the condition or disease to be treated, diagnosed, or prevented. Objectives may focus on dose-response, type of patient, frequency of dosing, or numerous other characteristics of safety and efficacy. The drug candidate, ErepoXen, is now in Phase III clinical trials in Russia and Phase II trials in India. The data to date from these trials show a substantial improvement 2-4 times dosing reduction over all existing marketed drugs which generate $7.2B in sales. The company will seek to outlicense this candidate to a large pharmaceutical company that has the capacity to develop and sell this large market drug. OncoHist The regulatory filing work for a Phase II trial in the United States for Acute Lymphocytic Leukemia (AML) is under way with hopes for an IND filing end of this year. This drug has orphan designation in the US and Europe for AML. OncoHist is now in Phase II clinical trials in Russia, where the data have shown that the OncoHist drug candidate is safe and well-tolerated by patients with to date no toxic effects that are universal in leukemia and other cancer treatments. Due to the potential nontoxic effects, Dana Farber Cancer Institute in Boston, one of the world's leading cancer research and treatment institutes, is researching many other potential therapeutic applications. Also, there were encouraging signs of clinical effects. ImuXen a Phase II clinical trial for the treatment of Multiple Sclerosis (MyeloXen) is under way in Russia. MyeloXen is the lead drug candidate within the ImuXen platform. So far, the trials have shown response rates that are promising. More reporting on this trial will be issued over the course of this year. Patent protection is virtually essential in the pharmaceutical and biotechnology industry. That's because of the enormous amount of time and money involved in the development of a drug product. Intellectual property law provides a structure for rewarding innovators by granting monopoly rights for their patented technologies. These monopoly rights are critical because they provide a way for a company to recoup its Research and Development investments. For a pharmaceutical company that engages in developing drugs, its core technology represents one of its most valuable assets. The need for strong patent protection to cover its core technology is vital, and this is well-known and publicized in the healthcare industry. Xenetic Biosciences has intellectual property protection surrounding its proprietary technologies. Patents and patent applications are associated with each of the 3 main technology platforms : The PolyXen technology area, the ImuXen technology area, and the OncoHist technology area. Xenetic Bioscience's patents and patent application portfolio plus its continuing patent-related efforts are undertaken to provide Xenetic Biosciences with the broadest possible patent protection for its products in critical markets. Although a few of PolyXen's early fundamental patents will expire prior to product launch, Xenetic Biosciences has obtained and/or is pursuing "follow-on" patent protection associated with linkage, protein, and derivative aspects of this technology to extend protection. The ability to exclude the competitors of Xenetic Biosciences from using its technologies after the launch of any of its products is virtually impossible without an agreement with the management of Xenetic because of the number of intellectual property assets, the priority dates of the patents and patent applications (which establish the patent expiration dates), the ability to obtain patent term extensions under the Hatch-Waxman Act, the ongoing prosecution of its patent applications, the continuing efforts of Xenetic Bioscience in filing patent applications, and the Orphan Drug status for its OncoHist drug candidate. In summary the average patent life for theccore of the technologies extends well into the next decade. Ray Dirks and his team suggest that readers/investors place no more than 1% of the funds they devote to common stocks in any one security. It's best to diversify! Disclosure: The information contained in this Report contains forward-looking statements relating to the developments of the featured company's products, services and future operating results or the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words "believe,", "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect performance include, but are not limited to, those factors that are discussed in each Company's most recent reports and/or registration statements filed with the Securities and Exchange Commission. Visitors to this Internet Site are cautioned not to place undue reliance on these forward-looking statements. These statements have not been independently verified by the officers, directors or employees of Corporate Profile, LLC .com. The information on this Internet Site has been submitted by journalists and analysts or provided by the companies contained herein or other sources believed to be reliable. Corporate Profile, LLC has not independently verified the information provided to it by third parties. Each individual should perform his or her own independent analysis before investing. The information contained herein is neither an offer nor a solicitation to buy any of the securities of the companies contained herein. Investing in securities is speculative and contains a high element of risk |
Posted at 03/6/2014 07:52 by buywell2 .................... GOOD THINGS COMING FOR XENETIC ....................Use Flash link after entering details to listen Whilst Xenetic BioSciences was my 3rd choice in my BioTech stock picks , and I have referred to it as a 'Wild Card' choice before, albeit with the potential of being a 10 BAGGER PLUS from it's AIM Listing days. I have now taken it OFF the 'Wild Card' List and placed it in my TOP Picks. The CEO and his BOD have done a GREAT Job of de-risking drug development and the USA move has added value already to existing shareholders with MUCH MORE set to come. To anyone following my Source BioScience Group (SBS) or Cyprotex Group (CRX) threads which are BOTH Small Cap Pharma Biotech stocks , BOTH recently acquired USA companies or companies with existing USA operations and BOTH have attracted MAJOR INSTITUTIONAL BUYING over the last 12 to 18 months . BOTH use the same NOMAD as Xenetic BioSciences Cyprotex also operates in Watertown, Massachusetts which is 6 MILES AWAY FROM THE NEW XENETIC BIOSCIENCE LABS IN LEXINGTON , after acquiring Apredica USA Cyprotex now also have a GLP LAB in Kalamazoo Michigan 386 miles away after acquiring CeeTox USA Source BioScience are looking to expand their footprint into other parts of the USA, already in California and Atlanta(two labs) .... I expect Massachusetts will be next as it is the BIGGEST PHARMA BIOTECH HUB in the whole of the USA. Coincidence ? Time will tell , but CRX and SBS BOTH offer testing and services to Pharma companies to get drug compounds through Pre-Clinical trials and identify any problems together with suggested solutions that sometimes occur with a new drug molecule , it is my hope to see the 3 Brit companies co-operate/collabora .................... NOW COMES THE CUNNING PLANS .................... ErepoXen® Phase 2 FDA compliant clinical trial results out of Australia/New Zealand by the end OF THIS MONTH. My take is that THIS RESULT IS GOING TO BE EXCELLENT AS XENETICS FUTURE IS RIDING UPON IT THEY HAVE ALREADY SHOWN TO BE CIRCA 300% BETTER THAN EXISTING CHRONIC ANEMIA TREATMENTS IN A PREVIOUS NON FDA COMPLIANT PHASE 2 TRIAL THIS IS NOT A NEW DRUG IT IS A REFORMULATED DRUG USING XENETIC TECHNOLOGY TO MAKE IT LONGER LASTING AND WITH BETTER EFFICACY The Xenetic strategy for the rest of 2014 is either Plan A or Plan B Plan A Xenetic are in talks now with a NUMBER of BIG Pharmas regarding ErepoXen® Their intention is to OUT-LICENCE ErepoXen® to one of these BIG Pharma companies, great phase 2 results will be KEY. A licence will involve an upfront initial payment in my opinion of circa $50m plus % payments based upon sales and the BIG Pharma taking ErepoXen® through Phase 3 trials and approval at their expense. Such an upfront licence fee will FUND the development of Xenetic ORPHAN drugs XENETIC INTEND TO FUND AND DEVELOP THEIR ORPHAN DRUG PIPELINES THEMSELVES Xenetic has enough cash to fund it's program for the next year Xenetic plans to list on NASDAQ in either the 3rd Quarter or 4th Quarter of 2014 Again an upfront licence fee will PAY FOR THE NASDAQ LISTING Plan B If BIG Pharma plays games re ErepoXen® then the NASDAQ Listing goes ahead anyway but with a share issue based upon trial results coming out of Russia/India and the Dana Faber Institute The most exiting of these which will attract USA investors BIGTIME is Xenetics AML candidate which has already been granted USA Orphan status Xenetics ONCOHIST candidate for acute myeloid leukemia(AML) Initial results from Dana Faber show this new drug candidate HAS NEARLY DOUBLE the efficacy of the BEST CURRENT AML DRUG ON THE MARKET ( 55% V 30% ) But there's more During other tests at the Dana Faber Institute the Oncohist candidate has also shown it could be effective against 1. A NUMBER OF OTHER CANCERS 2. A NUMBER OF OTHER LEUKEMIAS 3. A NUMBER OF OTHER LYMPHOMAS The Dana Faber Institute scientist involved has said that ONCOHIST is the BEST thing he has seen in TWENTY YEARS Re Leukemia Oncohist is the ONLY treatment that attacks the leukemia cells themselves and does NOT kill other healthy cells ie it is PURELY SELECTIVE in its target VERY VERY EXCITING And why Xenetic just might become another SHIRE |
Posted at 06/5/2014 10:40 by buywell2 Another class appointment and I think Baxter Healthcare with 10% of Xenetic are now behind these latest appointments , all AmericansXenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors LEXINGTON, Mass., May 5, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Mark Leuchtenberger as Non-Executive Chairman of the Board of Directors. Scott Maguire, CEO of Xenetic Biosciences said: "We are extremely pleased to welcome Mark as Chairman of the Board of Xenetic. His extensive track record as an experienced biopharmaceutical CEO and board member in both North America and Europe and his proven ability to build and manage successful organizations will be invaluable in helping Xenetic grow into a leading U.S. biopharmaceutical company and achieve our corporate goals." "I am honored to join the Xenetic Board of Directors as Non-Executive Chairman, particularly at this important juncture in the Company's development," said Mark Leuchtenberger. "I believe that the Company's drug candidates are poised to offer great benefits to patients in important areas of unmet medical need and I look forward to working with the whole Xenetic team to progress these programs through clinical development and to market." Mark Leuchtenberger brings substantial biopharmaceutical experience to his role as Non-Executive Chairman. He is currently the President and CEO of Acusphere, Inc., a late-stage, specialty pharmaceutical company focused on cardiac imagery, with a lead program in Phase 3 clinical development. Before joining Acusphere in 2013, Mr. Leuchtenberger served as President, Chief Executive Officer and a member of the Board of Directors at Rib-X Pharmaceuticals from 2010 to 2013. He also served as President and Chief Executive Officer at Targanta Therapeutics, where he led the company's initial public offering in 2007 and its acquisition in 2009, and at Therion Biologics from 2002 to 2006. Prior to Therion, Mr. Leuchtenberger worked as a senior officer at Biogen Idec, where he led the Avonex® development and launch in the U.S. In addition, he has served as Chairman of the Board for the Massachusetts Biotechnology Council and is currently a Trustee of Beth Israel Deaconess Hospital. Mr. Leuchtenberger holds an M.B.A. from Yale's School of Management and a B.A. from Wake Forest University. Mr. Leuchtenberger will succeed Sir Brian Richards as Chairman of the Board. Sir Brian, who has chaired Xenetic's Board since June 2005, will continue to support the Company as Chair of the Scientific Advisory Board. "We are deeply grateful to Sir Brian Richards for his leadership and dedication to Xenetic. Although I will miss Sir Brian's guidance and professionalism, which I have relied upon for the last 9 years, this step was inevitable given our transition to the U.S. The Board and I cannot thank him enough for his contribution," said Scott Maguire. "I am delighted to be able to continue to support the Company in my role as Chair of the Scientific Advisory Board," said Sir Brian. "Xenetic is creating drugs with truly transformative potential and I look forward to contributing to that effort through the medium of the SAB." Xenetic also announced the appointment of Roman Knyazev, an experienced financial professional, to the Board of Directors. Mr. Knyazev is a senior investment manager at RUSNANO (the Russian state-sponsored nanotechnology fund) and is an appointee of SynBio, a RUSNANO-controlled entity and currently the largest shareholder of Xenetic. He has worked at RUSNANO for the last 5 years, prior to which time he worked at PriceWaterhouseCoope He is a member of the SynBio Board of Directors and is a nominated Non-Executive Director being appointed pursuant to the agreement entered into between Xenetic and SynBio, whereby SynBio is entitled to nominate two directors to the Xenetic Board subject to SynBio holding not less than 40% of the Company's equity share capital. Mr. Knyazev is also a Deputy Chairman at Pharmsynthez, PETAR and Nanolek. About Xenetic Biosciences Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for creating next generation biologic drugs by extending the efficacy and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications. Xenetic's lead product candidates include ErepoXen®, an improved, polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease and OncoHist®, a recombinant human histone H1.3 molecule which Xenetic is developing for the treatment of refractory and relapsed Acute Myeloid Leukemia (AML). Xenetic has entered into a license agreement with Baxter International, Inc. for the development of a novel series of polysialylated blood coagulation factors. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the Company's website at |
Posted at 12/1/2014 18:52 by ashthorpedo General Sales and Leasing Inc will change it name to Xenetic Biosciences Inc on or around 14 January 2014.hxxp://www.4-traders General Sales and Leasing Inc : GENERAL SALES & LEASING, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations During the fourth quarter of our fiscal year ended August 31, 2013, we entered into discussions with Xenetic Biosciences plc ("XEN") regarding a potential all share offer for the entire issued and to be issued share capital of XEN (the "Acquisition"). On November 12, 2013, we reached an agreement on the terms of a recommended proposal for the Acquisition under which we will acquire the entire issued and to be issued share capital of XEN. As XEN is a UK based company trading on the AIM London Stock Exchange, the Acquisition is to be effected by means of a scheme of arrangement (the "Scheme") under Part 26 of the Companies Act in the UK by filing a Part 8 Claim with the High Court in London (which was filed on or about November 21, 2013). The Scheme needs to be approved by both 75% of the shareholders of XEN as well as the High Court in London (after a determination of fairness of the transaction) before becoming effective. On December 17, 2013, XEN announced that a majority in number of Xenetic Shareholders who voted (either in person or by proxy), representing 99.9% per cent by value of all Xenetic Shares held by such Xenetic Shareholders, voted in favor of the resolution to approve the Scheme. In addition, a special resolution to facilitate the implementation of the Scheme was passed by the requisite majority of the XEN shareholder votes cast in person or by proxy. On November 12, 2013, as part of the Scheme, we also entered into an Agreement of Conveyance, Transfer and Assignment of Subsidiaries and Assumption of Obligations with our largest shareholder, Oxbridge Technology Partners, SA ("Oxbridge"), pursuant to which Oxbridge will acquire all of the rights to our current business operations through the purchase of all the shares of our two wholly owned subsidiaries, Shift It Media and General Aircraft, Inc. (the "Hive Out" Agreement). Under the Hive Out Agreement, Oxbridge will cancel its 100,000,000 Common Shares in exchange for: (a) the shares of our two subsidiaries, and (b) the payment of US$430,000 in cash, subject, among other things, to the Scheme becoming Effective. The assets and liabilities associated with such businesses will thereby be transferred to Oxbridge and Oxbridge's 100,000,000 Shares will be cancelled and returned to treasury once the Scheme becomes effective. Under the Scheme, we will issue to the XEN shareholders 56 shares of our common stock for each 175 shares of their common stock. This will result in our immediately issuing an expected total of 130,520,137 shares of our common stock to the XEN Shareholders, which, following our planned 10 to 1 reverse share split and the cancelation of the shares held by Oxbridge in the Hive Out Agreement, will represent over 97% of our issued and outstanding shares. 5 Table of Contents As an additional step toward completion of the Acquisition, our board of directors and a majority of our shareholders have approved a change in our corporate name to "Xenetic Biosciences, Inc." and a reverse split of our common stock on a 1 for 10 basis. In connection with the reverse split, the par value of our common stock will also be increased from $0.001 to $0.01 per share. The effective date of these changes in the U.S. over-the-counter securities markets is expected to be on or about January 14, 2014, pending final approval of their effectiveness by FINRA. In the event that the Acquisition is consummated, certain of the officers and directors of XEN will assume management of our company, and, upon the divestment of our aircraft and advertising subsidiaries, we will focus our business activities exclusively on the business of XEN. |
Posted at 12/8/2013 14:53 by buywell2 Re all these RNS's we have been gettingGetting a Nasdaq listing would cost $ Millions .... but there is another way 16 July 2013 XENETIC BIOSCIENCES PLC Xenetic Biosciences seeks to effect its migration to the United States The board of Xenetic Biosciences plc ("Xenetic") notes the recent share price movement. It is able to confirm that it is currently seeking to identify a United States ("US") company ("US Counterparty") suitable to make an all share offer for the entire issued and to be issued share capital of Xenetic, to be effected by a UK Court sanctioned scheme of arrangement ("Scheme") under the Companies Act 2006 ("Possible Offer"). By this method, Xenetic hopes to achieve access to a quotation on a US stock market more easily, more quickly and in a more cost-effective manner than would be possible were it to apply for such a quotation itself. As previously announced by Xenetic, it has been implementing its longer term strategy as regards the migration of its corporate seat to, and its expansion in, the US, noting the significant value gap that exists between the biotechnology sector in the UK and in the US where the Company believes the sector is better understood and more widely followed. Any Possible Offer would be conditional on Xenetic agreeing terms with a suitable US Counterparty and all relevant US legal and regulatory requirements being satisfied to enable the migration to be completed in the manner intended. This is an announcement falling under Rule 2.4 of the Code. It does not represent a firm intention by any person to make an offer under Rule 2.7 of the Code. There can be no certainty that any offer will ultimately be made and as of the date of this announcement, Xenetic is not in discussions with any US Counterparty. Background The Board of Xenetic ("Xenetic Board") believes that at the present time smaller quoted bioscience companies, in general, have a higher profile and a better investor following in the US than is found in European markets in general and in the UK market, in particular. It believes that by achieving a quotation for Xenetic on a US stock market, significant benefits will accrue to Xenetic and its shareholders including, but not exclusively: · the ability to attract and incentivise qualified personnel with orphan drug development and launch experience; · easier access to finance; · a better rating of Xenetic's shares; and · higher levels of share trading liquidity. The Xenetic Board has considered a number of options to achieve its goal, including seeking a quotation of Xenetic's shares directly on a US stock market and seeking a merger with an existing US quoted biotechnology company with complementary activities. Following careful consideration of the issues the Xenetic Board determined that the best way is to be acquired by a SEC reporting, unlisted company, which can achieve a quotation on a major US stock market within a reasonable period, and to effect such an acquisition by a Scheme. Xenetic's plan is for it to be acquired on a share-for-share basis by a US Counterparty, where the level of effective dilution to Xenetic's shareholders is modest and agreed in advance. This means that, other than for an acceptable level of dilution (which is deemed to be the "cost" of achieving Xenetic's aims) and the fees and costs of the Possible Offer, the entity formed by the completion of the Possible Offer will be as near as possible the same entity as Xenetic, with the same assets and liabilities, save that it would have a new US holding company. Xenetic hopes to conclude the process of securing a Possible Offer during 2013. On the completion of any Possible Offer it is expected that Xenetic's shares will cease to be traded on AIM. It is Xenetic's intention to seek a quotation of the US Counterparty's shares on a US Exchange with minimal delay to minimise the period during which on-market trading will not be possible. Possible US Counterparties Any potential US Counterparty or person representing such a company interested in discussing a possible transaction with Xenetic along the lines set out herein should contact Adam Hart at adam.hart@londonbrid |
Posted at 18/7/2013 08:04 by buywell2 Worth a read Worth a read again cos I made a couple of mistakes Xenetic Biosciences expects higher rating from US switch Xenetic Biosciences (LON:XEN) is finally embarking on the process of "serious value" growth, according to its chief executive. This week Xenetic announced it is searching for a suitable candidate to reverse into to get a US listing, while the company's own development programmes for potential blockbuster drugs for western markets also starts soon. Chief executive Scott Maguire recently colourfully compared this process as being like a "battleship leaving the dock". He's referring to the first western clinical trial of ErepoXen for treating chronic anaemia, which is starting in Australia at the end of this month or next - one of several drugs in the firm's portfolio and a candidate that the firm wholly controls. Maguire explains that previously Xenetic has been purely research-based, relying on out-licensing partnerships and collaborations with groups in India and Russia. But, following a fundraising last year, the company has now begun the process of evolving into a drug developer, able to test and commercialise its own products. Maguire is so excited about this transition because, not only does if offer potentially large rewards for shareholders, but also because the firm's portfolio itself is highly promising. Xenetic specialises in developing orphan drugs for rare diseases, which have multi-billion dollar potential. Orphan drugs are fast-tracked to the market because they typically address diseases and conditions for which there are few, if any, medications. Now, following the firm's undeniable progress thus far, what is needed, is delivering on plans and, of course, securing financing, reckons Maguire. "As I see it, as management, the science is working and it's going to come down to a function of execution and money to deliver on the promise, because it's clear that these products we have in development have blockbuster potential and those are not my words, those are words from the investment and strategic community," he said. And Maguire highlighted all three of its technological platforms - PolyXen, ImuXen, OncoHist - have products in at least phase 2 clinical trials. Currently, its main focus is ErepoXen - the firm's most advanced product and likely to be the key share driver. Ironically, perhaps, this drug is one that does not fit into the firm's orphan strategy, in that it is a big, mass-market candidate. Maguire says the plan is to complete a dose finding study for western markets in December this year before striking a deal. "The goal of ErepoXen is to out-license as soon as allowable and there is already some interest in this product," he adds. "This is a big market drug, very expensive clinical trials, so we are going to be seeking a partner to out-license this as soon as we have data coming out of Australia/New Zealand. He said these locations were chosen because it is cost effective to run big market drug trials there, and the structure of the trials reflects the Food & Drug Administration (FDA) format so it's an easy transition into the US or Europe markets after phase 2 trials. Importantly, however, in Russia, where the drug is currently in trials, there is a chance to see revenues from ErepoXen sooner. In Russia, Xenetic hopes to see a commercial launch of the drug in the second half of next year and it will be receiving a 10% royalty on its sales in Russia. Another candidate the firm is excited about, and which will be added to its portfolio for the western markets, is OncoHist for acute myeloid leukaemia. Maguire told a conference call last month that he was "particularly" excited about this drug, which he said had "multi-billion dollar" potential. OnCoHist binds itself to leukaemia cells and leaves healthy cells alone, so there are no serious side effects. Maguire said a world-leading specialist described it as being the first novel mode of action for the disease he had seen in 20 years. The firm continues to test the efficacy of this drug and crucial phase 2 data is expected this summer. Part of the plans to expand into western markets is the move this September of staff to lab and development operations to Boston, USA - the world's leading centre for orphan drug development. Xenetic has also just announced it will look for a merger with an SEC reporting, unlisted US company, a move that will enable it get a quote on a major US stock market within a reasonable period. It wants to agree a deal in 2013, a move that will also see it de-list from AIM. Maguire said the long term benefits of being a US-centric organisation will become apparent as US markets give "significantly" greater value to firms like Xenetic with its broad proprietary drug pipeline. [...] buywell2 17 Jul'13 - 19:39 - 675 of 676 0 0 edit Thank you Earnest So to explain in more simple terms cos I am a tad thick at times I know and from some of the posts here several are a lot thicker than me. But since I have drawn the short straw in creating the thread I will put my spin on the last post .... This is MY take ....... 1. ErepoXen is due to start Phase 11 human trials in Australia IMMINENTLY even by the end of THIS MONTH ... which should attract a tad of XEN buying I would expect. 2. Interest from potential western partners has been EXPRESSED and they are tracking the data from these trials as they seek to DE-RISK themselves before committing spending a shedload of cash to take ErepoXen to the APPROVAL stage and then commercialize/advert 3. Meantime our Russian partners have started their OWN DOMESTIC RUSSIAN PHASE 111 trials and have dosed the first patient back in May 2013. 4. This means Xenetic has TWO CHANCES of scoring serious lolly on ErepoXen a) MEGABUCKS from a Western Capitalista deal after Phase 11 data gets released out of Australia , at which point I see one of the 'interested parties' getting the paper signed before someone else beats them to the punch ..... and b) Decent revenues to cover other drug developments in the pipeline from the 10% that Xenetic stand to get from ErepoXen sales in Russia when Phase 111 trials end and the state of Russia gives ErepoXen their approval .... which looks in my opinion to be VERY good when one remembers that EPO is not a new drug .... remember EPO has been used before but has gone out of patent. ErepoXen is NOT a step into the unknown for Xenetic. What Xenetic has done is to reformulate it and apply their own unique IP/ technology so that the drug works MUCH better than it ever did before , and one dose is efficacious for circa 1 MONTH. The data from the new trials SHOULD make ErepoXen the BEST performer on the marketplace V what's out there now. It is my opinion .... and remember I am a conservative sort of guy .... that the clever new guys recently taken on by Scott are going to use info and any EARLY indications from the trials to MAXIMISE XEN shareholder value when it comes to the reverse takeover/Shell deal in the USA. It is my considered opinion ..... and if you read my advfn posts ..... I consider much more than most posters ..... that WHOEVER gets to deal with XEN in the USA are going to make a MINT. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
